Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Assets (2016 - 2025)

Historic Assets for Fortress Biotech (FBIO) over the last 13 years, with Q3 2025 value amounting to $181.4 million.

  • Fortress Biotech's Assets rose 4274.46% to $181.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $181.4 million, marking a year-over-year increase of 4274.46%. This contributed to the annual value of $144.2 million for FY2024, which is 1391.01% down from last year.
  • As of Q3 2025, Fortress Biotech's Assets stood at $181.4 million, which was up 4274.46% from $159.9 million recorded in Q2 2025.
  • Fortress Biotech's 5-year Assets high stood at $418.2 million for Q2 2021, and its period low was $127.1 million during Q3 2024.
  • Over the past 5 years, Fortress Biotech's median Assets value was $181.4 million (recorded in 2025), while the average stood at $256.1 million.
  • In the last 5 years, Fortress Biotech's Assets surged by 7094.1% in 2021 and then crashed by 5347.12% in 2023.
  • Fortress Biotech's Assets (Quarter) stood at $396.5 million in 2021, then dropped by 25.78% to $294.3 million in 2022, then tumbled by 43.08% to $167.5 million in 2023, then dropped by 13.91% to $144.2 million in 2024, then increased by 25.78% to $181.4 million in 2025.
  • Its last three reported values are $181.4 million in Q3 2025, $159.9 million for Q2 2025, and $178.1 million during Q1 2025.